NEW YORK, Oct. 28, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC announces that a securities class action has been filed in the United States District Court for the Southern District of Florida on behalf of those who purchased shares of Catalyst Pharmaceutical Partners, Inc. ("Catalyst or the Company") (NasdaqCM:CPRX), during the period between October 31, 2012 and October 18, 2013, inclusive (the "Class Period").
The complaint charges Catalyst and certain of its executives with violations of federal securities laws. In particular the Complaint asserts that Catalyst failed to disclose during the Class Period that one of its competitors has already been manufacturing a drug biologically equivalent to Firedapse–a drug Catalyst has claimed to be developing and marketing–and providing it to patients to treat Lambert-Eaton Myasthenic Syndrome free of charge, through a compassionate use program.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Catalyst you have until December 24, 2013 for investors to seek a lead plaintiff appointment. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.